(Q51738913)

11 April 2018

title

Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. (English)

1 reference

11 April 2018

author name string

Anis Aziz

1

1 reference

11 April 2018

Annie Lessard

2

1 reference

11 April 2018

Katherine Moore

3

1 reference

11 April 2018

Hélène Hovington

4

1 reference

11 April 2018

Eva Latulippe

5

1 reference

11 April 2018

Hélène Larue

6

1 reference

11 April 2018

Yves Fradet

7

1 reference

11 April 2018

Louis Lacombe

8

1 reference

11 April 2018

publication date

16 December 2010

1 reference

11 April 2018

published in

BJU International

1 reference

11 April 2018

volume

108

1 reference

11 April 2018

issue

4

1 reference

11 April 2018

page(s)

531-537

1 reference

11 April 2018

Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Cyclooxygenase-2: a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09909.X

10.1111/J.1464-410X.2010.09909.X

21 January 2018

Identifiers

DOI

1 reference

11 April 2018

1 reference

11 April 2018